Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios-Athanasios Dimopoulos

Showing results (191-200 of 283) with videos related to

Pageof 29
Sort By:
Leukemia & Lymphoma|January 11, 2019
Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patientsMaria Gavriatopoulou, Despina Fotiou, Ursula Koloventzou, et al.
BMC Cancer|December 14, 2018
Management of uterine sarcomas and prognostic indicators: real world data from a single-institutionAnastasios Kyriazoglou, Michael Liontos, Dimitrios C Ziogas, et al.
Trends in Analytical Chemistry : TRAC|November 25, 2020
Analytical methodologies for the detection of SARS-CoV-2 in wastewater: Protocols and future perspectivesNikiforos Alygizakis, Athina N Markou, Nikolaos I Rousis, et al.
Microorganisms|April 3, 2021
Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 InfectionIoannis V Kostopoulos, Nikolaos Orologas-Stavrou, Pantelis Rousakis, et al.
Diseases (Basel, Switzerland)|September 27, 2023
Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron EraIoannis Ntanasis-Stathopoulos, Charalampos Filippatos, Maria Gavriatopoulou, et al.
Blood|February 26, 2025
Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myelomaEvangelos Terpos, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, et al.
Vaccines|September 23, 2022
Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted AgentsFlora Zagouri, Alkistis Papatheodoridi, Michalis Liontos, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 3, 2025
Second Primary Malignancies and Disease Transformation in Patients With Symptomatic Waldenström's MacroglobulinemiaMaria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Vasiliki Spiliopoulou, et al.
The Science of the Total Environment|October 1, 2022
Delta SARS-CoV-2 variant is entirely substituted by the omicron variant during the fifth COVID-19 wave in Attica regionAikaterini Galani, Athina Markou, Lampros Dimitrakopoulos, et al.
Anti-Cancer Drugs|February 2, 2023
Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigmAristotelis Bamias, Roubini Zakopoulou, Kimon Tzannis, et al.
Pageof 29

Showing results (191-200 of 283) with videos related to

Sort By:
Pageof 29
Leukemia & Lymphoma|January 11, 2019
Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patientsMaria Gavriatopoulou, Despina Fotiou, Ursula Koloventzou, et al.
BMC Cancer|December 14, 2018
Management of uterine sarcomas and prognostic indicators: real world data from a single-institutionAnastasios Kyriazoglou, Michael Liontos, Dimitrios C Ziogas, et al.
Trends in Analytical Chemistry : TRAC|November 25, 2020
Analytical methodologies for the detection of SARS-CoV-2 in wastewater: Protocols and future perspectivesNikiforos Alygizakis, Athina N Markou, Nikolaos I Rousis, et al.
Microorganisms|April 3, 2021
Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 InfectionIoannis V Kostopoulos, Nikolaos Orologas-Stavrou, Pantelis Rousakis, et al.
Diseases (Basel, Switzerland)|September 27, 2023
Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron EraIoannis Ntanasis-Stathopoulos, Charalampos Filippatos, Maria Gavriatopoulou, et al.
Blood|February 26, 2025
Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myelomaEvangelos Terpos, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, et al.
Vaccines|September 23, 2022
Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted AgentsFlora Zagouri, Alkistis Papatheodoridi, Michalis Liontos, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 3, 2025
Second Primary Malignancies and Disease Transformation in Patients With Symptomatic Waldenström's MacroglobulinemiaMaria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Vasiliki Spiliopoulou, et al.
The Science of the Total Environment|October 1, 2022
Delta SARS-CoV-2 variant is entirely substituted by the omicron variant during the fifth COVID-19 wave in Attica regionAikaterini Galani, Athina Markou, Lampros Dimitrakopoulos, et al.
Anti-Cancer Drugs|February 2, 2023
Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigmAristotelis Bamias, Roubini Zakopoulou, Kimon Tzannis, et al.
Pageof 29